{"relation": [["", "STARTED", "COMPLETED", "NOT COMPLETED", "Adverse Event", "Lost to Follow-up"], ["Darunavir(TMC114)/Eravirine(TMC125)", "10", "8", "2", "1", "1"]], "pageTitle": "Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects. - Study Results - ClinicalTrials.gov", "title": "", "url": "https://clinicaltrials.gov/ct2/show/results/NCT00460746?sect=X015&view=results", "hasHeader": true, "headerPosition": "FIRST_ROW", "tableType": "RELATION", "tableNum": 4, "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990123.20/warc/CC-MAIN-20150728002310-00036-ip-10-236-191-2.ec2.internal.warc.gz", "recordEndOffset": 855199979, "recordOffset": 855191777, "tableOrientation": "HORIZONTAL", "textBeforeTable": "Participant Flow: \u00a0 Overall Study Darunavir/ritonavir (DRV/r) combined with Etravirine ([ETR] also known as TMC125) when current protease inhibitor(s) (PIs), non-nucleoside reverse transriptase inhibitor(s) (NNRTIs), and enfuviritide (ENF) were replaced by DRV/r and ETR in subjects with intolerance to ENF. Darunavir(TMC114)/Eravirine(TMC125) Description \u00a0 Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: TMC125, Darunavir; Ritonavir Intervention: HIV", "textAfterTable": "\u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics Population Description Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. No text entered. Reporting Groups \u00a0 Description Darunavir(TMC114)/Eravirine(TMC125) Darunavir/ritonavir (DRV/r) combined with Etravirine ([ETR] also known as TMC125) when current protease inhibitor(s) (PIs), non-nucleoside reverse transriptase inhibitor(s) (NNRTIs), and enfuviritide (ENF) were replaced by DRV/r and ETR in subjects with intolerance to ENF. Baseline Measures \u00a0 \u00a0 Darunavir(TMC114)/Eravirine(TMC125) \u00a0 Number of Participants \u00a0 [units:\u00a0participants] \u00a0 10 \u00a0 Age \u00a0", "hasKeyColumn": true, "keyColumnIndex": 0, "headerRowIndex": 0}